Feedback inhibition-the inhibition of the first enzymatic reaction unique to a pathway by the end product of that pathway-plays an important role in regulating various biosynthetic sequences. In bacteria and also in higher organisms this mechanism serves to control the formation of purines, pyrimidines, and amino acids.' Data presented in this communication demonstrate that the biosynthesis of certain sugar nucleotides in rat liver is likewise subject to feedback inhibition.
The pathways leading to the formation of UDP-N-acetyl-D-glucosamine (UDPAG)2 and CMP-N-acetylneuraminic acid (CMP-NAN) are outlined in Figure   1 .3 Both sugar nucleotides represent the activated form to which the respective sugars must be converted prior to incorporation into glycoproteins and other macromolecules. UDPAG and CMP-NAN may therefore be considered the end products of the multistep pathways leading to their formation. Each of these end products inhibits the first enzyme of the pathway which is unique to its biosynthesis.
Materials and Methods. Other nucleotides and sugar nucleotides were purchased from commercial sources. D-Glucosamine-6-P was a gift of Dr. L. Glaser. The crystalline barium salt of D-fructose-6-P was obtained from Boehringer and Sons. Puromycin and the aminonucleoside of puromycin were purchased from Nutritional Biochemicals Corp.
The following chromatographic solvents were used: I, ethanol-i M ammonium acetate, pH 7.5 (75:30); II, ethanol-i M ammonium acetate, pH 3.8 (75:30); III, isobutyric acid-1 M NH40H (10: 6); IV, isoamyl acetate-acetic acid-water (3:3:1).
UDP-N-acetylhexosamine was isolated from rat livers by ethanol extraction, adsorption to and elution from charcoal, and paper chromatography in solvents I and II. 8 The method was modified in the experiment described in Figure 2 by substituting electrophoresis at pH 3.7 for the charcoal adsorption step, and by chromatography of the product in solvents I, II, and III. Radioactivity of the purified sugar nucleotides was determined in a liquid scintillation spectrometer, in a system containing 0.5 ml of water and 8.0 ml of Bray's solution. ' Preparation and assay of enzymes from rat liver: iGlutamine-D-fructose-6-P transaminase was prepared by the method of Pogell and Gryder.10 The ammonium sulfate fraction (purified fourfold over the 18,000 X g supernatant solution) was subjected to filtration through Sephadex G-25 prior to use. The enzyme was assayed in a reaction mixture consisting of 30 MAmoles sodium phosphate buffer of pH 7.6, 12 Mumoles iglutamine, 5 Aumoles D-fructose-6-P, and the enzyme, in a total volume of 1 ml. Incubation was carried out for 30 min at 370 and terminated by heating for 1 min at 1000. The suspension was then centrifuged and an aliquot of the supernatant solution assayed for hexosamine by the method of Ghosh et al. "1 The enzyme which converts UDPAG to N-acetyl-D-mannosamine (UDPAG 2-epimerase) was prepared by a slight modification of the method of Cardini and Leloir.12 The assay was carried out in a reaction mixture which contained 30 JAmoles Tris buffer of pH 7.5, 15 JAmoles MgSO4, 5 ,smoles cysteine, 0.5 Mmole C14-labeled UDPAG (2400 cpm), and the enzyme, in a final volume of 0.2 ml. After a 15-min incubation the reaction mixture was heated for 1 min at 1000. One milliliter of a suspension of Dowex 1-X8 formate, containing enough resin (130 mg dry weight) to adsorb all the remaining C14-UDPAG, was added. An aliquot of the supernatant fluid, which contained the neutral N-acetylmannosamine, was plated and counted in an end-window gas flow counter. N-acetylmannosamine was shown to be the only neutral product by paper electrophoresis in 0.05 M sodium tetraborate. The rate of N-acetylmannosamine liberation was linear for at least 30 min and was proportional to enzyme concentration.
Glucosamine-6-P transacetylase was made by fractionating the supernatant solution from 100,000 X g centrifugation with solid (NH4)2SO4 between 40% and 70% saturation. In order to study the sugar nucleotide injected intraperitoneally at zero time with
Ilml of saline, and three with 1 ml of saline precursors of glycoproteins, rats were containing 15 mg of puromycin. A second simultaneously treated with puromycinto dose was administered at 1 hr to the two simulaneosly reatd wih puomycn to animals which were kept for the 2-hr period. stop protein synthesis' and with glucos-Glucosamine-C'4 (2.5 ,Sc, 0.25 pmole, in 0.5 amine-C'4 to label the nucleotide-bound ml of saline) was injected into the tail vein at zero time. All injections were performed N-acetylhexosamine pool. It was rea-under light ether anesthesia. At the times soned that if the synthesis of protein indicated, the animals were sacrificed, and the UDP-N-acetylhexosamine was isolated molecules were inhibited, the sugar nu-from the liver and counted as described in cleotide precursors of the carbohydrate Methods. chains of the glycoproteins should accumulate. The results of this experiment are shown in Figure 2 . In the puromycintreated and in the control rats, UDP-N-acetylhexosamine [UDP(AG)] accounts for most of the ethanol-soluble radioactivity at the three points selected for study.'8 In the control animals, both total activity and specific activity of the UDP(AG) pool were high 15 min after injection and declined to one tenth this value in 2 hr. In the puromycin-treated animals, incorporation of labeled glucosamine into sugar nucleotide occurred normally, but during the 2-hr experimental period there was no loss of counts from the UDP(AG) pool-no utilization of that pool had occurred. Furthermore, it appeared that the synthesis of UDP(AG) had also been impaired, since its specific activity did not fall in 2 hr, during which time the entire pool of UDP(AG) had turned over at least once in the control animal.'9 If synthesis had proceeded normally in the absence of utilization, the specific activity of UDP(AG) would have fallen to one third to one half its original value.
The cessation of UDP(AG) synthesis in the absence of utilization could have been due to depletion of available UTP when the normal cycle of UTP regeneration was interrupted, or to a feedback inhibition by the UDP(AG) on some enzymatic step of l00 lits biosynthetic pathway. In a preliminary trial, glucosamine-Cl4 was injected 30 min after the ad-80 ministration of puromycin; it was incorporated into 060 2 / UDP(AG) in a normal fashion, indicating that UTP was still available and that the activity of the en-40 _ zymes converting glucosamine-6-P to UDPAG (see In the animals pretreated with puromycin the incorporation of glucosamine-H3 into UDP(AG) was comparable to that in control animals, but the incorporation of glycerol-C'4 into nucleotide-linked acetylhexosamine20a was markedly depressed. The animal pretreated with the aminonucleoside of puromycin, which does not inhibit protein synthesis or prevent the normal turnover of UDP(AG), gave a result similar to controls.2'
The results of the experiments described above may best be explained by postulating that a mechanism of feedback inhibition is operating to control the biosynthesis of UDP(AG) in the liver. When UDP(AG) utilization stops because glycoprotein synthesis is impaired by puromycin, UDPAG prevents further synthesis of itself by inhibiting the first enzyme unique to its pathway, i.e., glutamnine-fructose-6-P transaminase. As a result, the incorporation of glycerol-Cl4 into UDP(AG) is inhibited in rats pretreated with puromycin, since glycerol must be converted to fructose-6-P before it can be incorporated into the hexosamine position of UDP (AG). The entry of glucosamine, on the other hand, bypasses this control step; it is therefore not affected by the feedback inhibition and its incorporation into UDPAG proceeds at a normal rate.
Inhibition of L-glutamine-D-fructose-6-P transaminase: The transaminase isolated from rat liver was found to be markedly inhibited by UDPAG (Fig. 3) . The kinetics of this inhibition are of the 90 ' competitive type (Fig. 4) , i.e., UDPAG 80 _ increases the Km for fructose-6-P without changing the maximal velocity. From 70 2xI05 M UDPAG the data in Figure 4 , the Km for fructose-60 6-P was calculated to be 8 does not inhibit at a concentrais expressed as amoles of glucosamine-6-P UDPAG, does not lnhlblt at a concentra-formed in 30 min. tion of 0.5 X 10-3 M, providing evidence that this is truly an end-product inhibition. Puromycin at 0.6 X 10-3 M had no effect on the enzyme. UDPAG at 7 X 10-4 M had no inhibitory effect on glucosamine-6-P transacetylase, the second enzyme on the pathway to UDP-acetylhexosamine formation.
These findings are in agreement with the results of the experiments performed in vivo. The transaminase, which is the first enzyme of the pathway, is inhibited by the end product, UDPAG, while the subsequent steps are not affected. This situation is similar to that observed in other systems of feedback inhibition in which only the first enzyme in the pathway is affected by the inhibitor. Inhibition of UDP-N-acetylglucosamine 2-epimerase by CMP-NAN: It was of interest to determine whether the pathway leading to the synthesis of CMP-Nacetylneuraminic acid was subject to a similar kind of feedback inhibition. One would expect a priori that the organism has some mechanism for controlling this entirely irreversible pathway (see Fig. 1 ), which would otherwise be a constant drain on the supply of UDPAG. The flow of substrate through this pathway must be quantitatively significant, since the N-acetylneuraminic acid and N-acetylglucosamine residues which occur in plasma glycoproteins in a ratio of, on the average, 1 to 2,23 are labeled at comparable rates. '4' 15 If that flow continued at its usual rate in the presence of puromycin, the label from the injected glucosamine would have been recovered predominantly in CMP-NAN, rather than in UDP(AG), as had been shown. UDPAG 2-epimerase isolated from the liver is inhibited by CMP-NAN as shown in Figure 5 . First it should be noted that the concentration of CMP-NAN required for 50 per cent inhibition of the enzyme is 30 times greater than the concentration of UDPAG required for 50 per cent inhibition of the transaminase. Second, the sigmoidal shape of the inhibition curve suggests that the affinity of the enzyme for CMP-NAN increases as it becomes more saturated with the inhibitor. It has been proposed that such sigmoidal curves may be due to the interaction of subunits.24' 5 Binding of CMP-NAN by UDPAG 2-epimerase appears not only to change the affinity of the enzyme for the inhibitor, but also its affinity for the substrate, UDPAG. As shown in Figure 6 , CMP-NAN decreases both the Km for UDPAG and the maximum velocity of the reaction. At low substrate concentration these effects tend to cancel one another and produce little or no inhibition, while at high substrate concentrations the Km effect is minimized and the decrease in velocity is apparent. This is best illustrated when the concentration of CMP-NAN is high (Fig. 6, curve C) . rThe kinetics of this reaction are further complicated by substrate inhibition at high substrate concentrations.
The effect of various nucleotides and sugar nucleotides on the epimerase is shown in Table 3 . This table illustrates the high specificity required of the inhibitor. No other compound tested, including N-acetylneuraminic acid and CMXP, shows significant inhibition even when present in high concentrations. The concentration of CMP-NAN required to inhibit the UDPAG 2-epimerase in vitro raises an interesting problem. The intracellular concentration of this nucleotide probably does not approach the concentration needed for inhibition. How then does the control mechanism operate in vivo? In view of the extensive intracellular organization of mammalian cells, it may be that the concentration of the inhibitor is sufficiently high at the site of enzyme action to have a significant effect.
Possible physiological role of the feedback control of sugar nucleotide synthesis: One may postulate at least two benefits which the control of the synthesis of UDP-Nacetylhexosamine and CI\IP-N-acetylneuraminic acid bring to the animal. Control of glutamine-fructose-6-P transaminase renders the synthesis of UDPAG relatively independent of the level of hexose-6-P, which fluctuates widely in response to feeding26 or changes in the rate of glycolysis.27 Furthermore, when the rate of glycoprotein synthesis is altered, the animal is enabled to adjust rapidly the rate of synthesis of UDPAG and CM\P-NAN to the requirement for these compounds. The level of the enzymes in the pathways to the sugar nucleotides may thus be kept high enough to cope with increased demand, without imposing on the animal the burden of continuous overproduction of sugar nucleotides. Preliminary experiments point out some possible consequences of uncontrolled synthesis of UDPAG. A single injection of 50 umoles of glucosamine increased the concentration of UDP(AG) in the liver by 3 ltmoles in 15 min, thus doubling the size of the pool. One rat, infused with 5 per cent glucosamine for 2.5 hr, had 17 jumoles of UDP(AG) in the liver. Such an enormous expansion of the UDP(AG) pool may strain the ability of the liver to maintain a proper level of other uridinecontaining nucleotides, with consequent aberrations not only in the metabolism of compounds containing galactose or glucuronic acid, but also in the synthesis of nucleic acid and protein.
There are conditions, such as exposure to penicillin, which will cause bacteria to accumulate large amounts of aminosugar nucleotides.1 This reflects a less rigid control of the production of these compounds in bacteria than in rat liver. To date, we have not been able to demonstrate any effect of UDPAG on the glutaminefructose-6-P transaminase isolated from Salmonella paratyphi A and Escherichia coli B. The possibility that bacteria regulate aminosugar nucleotide biosynthesis by repression-derepression or by feedback control of enzymes other than the transaminase has not been investigated.
Summary.-UDP-N-acetylglucosamine inhibits L-glutamine-D-fructose-6-phosphate transaminase, the first enzyme unique to its biosynthesis. Similarly, the formation of N-acetylmannosamine by UDP-N-acetylglucosamine 2-epimerase is inhibited by the end product, CMP-N-acetylneuraminic acid. Compounds closely related to these inhibitors have little or no effect.
The feedback inhibition of the L-glutamine-D-fructose-6-phosphate transaminase has been demonstrated in viva by the administration of puromycin, which prevents the utilization of UDP-N-acetylglucosamine.
consists of an equilibrium mixture of 2 parts of UDP-N-acetylglucosamine and 1 part UDP-Nacetylgalactosamine.8 19 The half life of UDP(AG) estimated from the three points in Fig. 2 (Bersohn and Isenberg, 1964) . Such a delocalization suggests that a phosphorescence study of DNA-acridine dye complexes might be fruitful. While singlet transitions from one molecule to another may occur via long-range dipole-dipole coupling, triplet migration presumably occurs only via wave-function overlap. It might be expected, therefore, that an intercalated dye molecule would interfere with the migration of triplet excitation. Conversely, any interference or interaction that could be shown might serve as a verification of the intercalation model. As will be seen, not only was the expected interaction observed, but this took the unexpected form of an energy transfer from an excited triplet of DNA to an excited singlet of the dye. An analysis of the data shows that the observed energy transfers are reasonable on the assumption of an intercalation model and may be taken as a verification of this model.
